Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Palatin TechnologiesFRA:PTN 32 Receivables Turnover is 2.43 as of Mar. 2026. GuruFocus rates FRA:PTN with a GF Score™ of 32/100. The stock has 5 warning signs investors should review. Among 842 Biotechnology companies, Palatin Technologies ranks worse than 75.53% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Palatin Technologies's Revenue for the
three
months ended in Mar. 2026 was €3.39 Mil. Palatin Technologies's average Accounts Receivable for the
three
months ended in Mar. 2026 was €1.40 Mil.
Hence, Palatin Technologies's Receivables Turnover for the
three
months ended in Mar. 2026 was 2.43.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Palatin Technologies Receivables Turnover Related Terms
Palatin Technologies Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Palatin Technologies's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PTN vs LEXX, CTXR, HIND: Receivables Turnover Comparison
For the Biotechnology subindustry, Palatin Technologies's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Palatin Technologies Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Palatin Technologies's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Palatin Technologies's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Palatin Technologies (FRA:PTN) has a Receivables Turnover of 2.43 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Palatin Technologies and its competitors. According to the industry distribution chart, Palatin Technologies ranks #636 out of 842 companies in the Biotechnology industry, placing it in the top 75.5%.
Is Palatin Technologies' Receivables Turnover too high?
Palatin Technologies' current Receivables Turnover is 2.43. The Biotechnology industry median Receivables Turnover is 5.29. Palatin Technologies' value of 2.43 is 54.1% below this industry median. Based on the distribution chart, Palatin Technologies ranks #636 out of 842 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Palatin Technologies has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Palatin Technologies' Receivables Turnover compare to LEXX and CTXR?
According to the Biotechnology industry distribution chart, Palatin Technologies ranks #636 out of 842 companies for Receivables Turnover. This places Palatin Technologies in the lower half of its industry. The industry median Receivables Turnover is 5.29. Palatin Technologies' value of 2.43 is 54.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Palatin Technologies's current Receivables Turnover of 2.43 is 54.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Palatin Technologies and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Palatin Technologies's current Receivables Turnover is 2.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Palatin Technologies stock overvalued right now?
Palatin Technologies (FRA:PTN) has a current Receivables Turnover of 2.43. The current Receivables Turnover is 2.43 and 54.1% below the Biotechnology industry median of 5.29. Palatin Technologies' overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Palatin Technologies (FRA:PTN), the current Receivables Turnover is 2.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. The Company's business is in one operating segment: life science.
32GF Score
Get the complete analysis for FRA:PTN
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PTN has been successfully added to your 
